IBio Stock Ticks Higher After Adding Three Cancer Antibody Programs

IBio Inc IBIO has added three anti-cancer targets to its pipeline of therapeutic candidates.
The Company seeks to change the drug development paradigm with the FastPharming Protein Expression System by reducing the time and cost to move from the initial concept to the clinic.
Accordingly, it has entered into a research services agreement with FairJourney Biologics SA to access novel display technologies and proprietary antibody libraries.
"We believe combining our 'speed-to-clinic' advantages and Glycaneering Technologies with the antibody optimization technologies provided by FairJourney may enable us to quickly develop differentiated cancer therapeutic antibodies with improved antibody-dependent cell-mediated cytotoxicity, or ADCC," said Martin B. Brenner, DVM, Ph.D., iBio's Chief Scientific Officer.
Price Action: IBIO shares are up 5.8% at $1.47 during the premarket session on the last check Friday.